Literature DB >> 34981129

[Local and locoregional treatment of intrahepatic cholangiocarcinoma].

Frank Wacker1, Cornelia Dewald2.   

Abstract

CLINICAL/METHODICAL ISSUE: In the new edition of the German S3-guideline published in June 2021, the diagnosis and treatment of cholangiocarcinoma (CCA) and gallbladder carcinoma are addressed for the first time. This article discusses the local and locoregional treatment options for intrahepatic CCA (iCCA). STANDARD RADIOLOGICAL
METHODS: Mortality is high in iCCA and the incidence is rising. In unresectable patients, treatment options include local and locoregional approaches. METHODICAL INNOVATIONS: Besides recommendations regarding surgery, biliary drainage, intraductal locoregional therapy and radiation therapy, two recommendations regarding interventional radiologic therapies are included in the updated S3-guideline. Percutaneous thermal ablation via radiofrequency or microwave ablation (RFA/MWA) is suggested for unresectable tumors with up to 3 cm in diameter as primary therapy and for recurrent tumors. In advanced, liver dominant iCCA, intra-arterial therapies such as transarterial radioembolization (TARE), transarterial chemoembolization (TACE) or hepatic arterial infusion (HAI) are recommended as single therapy or in combination with other therapies. ACHIEVEMENTS: Due to a lack of randomized controlled studies, the efficacy of locoregional therapies in iCCA is challenging to assess; however, various cohort studies, meta-analyses and review articles confirm their efficiency. PRACTICAL RECOMMENDATIONS: Interventional radiological therapies alone or in combination with systemic therapies have the potential to improve the prognosis of patients with iCCA. Due to the various therapeutic options, patients with iCCA should be treated in centers which cover the entire therapeutic spectrum.
© 2021. The Author(s), under exclusive licence to Springer Medizin Verlag GmbH, ein Teil von Springer Nature.

Entities:  

Keywords:  Interventional oncology; Intraarterial therapy; Intrahepatic cholangiocarcinoma; Locoregional therapy; S3-guideline

Mesh:

Year:  2022        PMID: 34981129     DOI: 10.1007/s00117-021-00946-9

Source DB:  PubMed          Journal:  Radiologe        ISSN: 0033-832X            Impact factor:   0.635


  31 in total

Review 1.  Cholangiocarcinoma 2020: the next horizon in mechanisms and management.

Authors:  Jesus M Banales; Jose J G Marin; Angela Lamarca; Pedro M Rodrigues; Shahid A Khan; Lewis R Roberts; Vincenzo Cardinale; Guido Carpino; Jesper B Andersen; Chiara Braconi; Diego F Calvisi; Maria J Perugorria; Luca Fabris; Luke Boulter; Rocio I R Macias; Eugenio Gaudio; Domenico Alvaro; Sergio A Gradilone; Mario Strazzabosco; Marco Marzioni; Cédric Coulouarn; Laura Fouassier; Chiara Raggi; Pietro Invernizzi; Joachim C Mertens; Anja Moncsek; Sumera Rizvi; Julie Heimbach; Bas Groot Koerkamp; Jordi Bruix; Alejandro Forner; John Bridgewater; Juan W Valle; Gregory J Gores
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2020-06-30       Impact factor: 46.802

2.  Intrahepatic cholangiocarcinoma: expert consensus statement.

Authors:  Sharon M Weber; Dario Ribero; Eileen M O'Reilly; Norihiro Kokudo; Masaru Miyazaki; Timothy M Pawlik
Journal:  HPB (Oxford)       Date:  2015-08       Impact factor: 3.647

Review 3.  MR-Guided Liver Interventions.

Authors:  Jakob Weiss; Rüdiger Hoffmann; Stephan Clasen
Journal:  Top Magn Reson Imaging       Date:  2018-06

4.  Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma.

Authors:  John Bridgewater; Peter R Galle; Shahid A Khan; Josep M Llovet; Joong-Won Park; Tushar Patel; Timothy M Pawlik; Gregory J Gores
Journal:  J Hepatol       Date:  2014-03-27       Impact factor: 25.083

5.  Biliary cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Authors:  J W Valle; I Borbath; S A Khan; F Huguet; T Gruenberger; D Arnold
Journal:  Ann Oncol       Date:  2016-09       Impact factor: 32.976

6.  Cholangiocarcinoma in Germany: Epidemiologic trends and impact of misclassification.

Authors:  Dirk Walter; Philip Ferstl; Oliver Waidmann; Jörg Trojan; Sylvia Hartmann; Andreas A Schnitzbauer; Stefan Zeuzem; Klaus Kraywinkel
Journal:  Liver Int       Date:  2018-10-08       Impact factor: 5.828

Review 7.  Clinical presentation, diagnosis and staging of cholangiocarcinoma.

Authors:  Alejandro Forner; Gianpaolo Vidili; Marco Rengo; Luis Bujanda; Mariano Ponz-Sarvisé; Angela Lamarca
Journal:  Liver Int       Date:  2019-03-25       Impact factor: 5.828

8.  Expert consensus document: Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA).

Authors:  Jesus M Banales; Vincenzo Cardinale; Guido Carpino; Marco Marzioni; Jesper B Andersen; Pietro Invernizzi; Guro E Lind; Trine Folseraas; Stuart J Forbes; Laura Fouassier; Andreas Geier; Diego F Calvisi; Joachim C Mertens; Michael Trauner; Antonio Benedetti; Luca Maroni; Javier Vaquero; Rocio I R Macias; Chiara Raggi; Maria J Perugorria; Eugenio Gaudio; Kirsten M Boberg; Jose J G Marin; Domenico Alvaro
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2016-04-20       Impact factor: 46.802

9.  Endoscopic ultrasound-guided fine needle aspiration biopsy of suspected cholangiocarcinoma.

Authors:  Mohamad A Eloubeidi; Victor K Chen; Nirag C Jhala; Isam E Eltoum; Darshana Jhala; David C Chhieng; Sujath A Syed; Selwyn M Vickers; C Mel Wilcox
Journal:  Clin Gastroenterol Hepatol       Date:  2004-03       Impact factor: 11.382

10.  [Diagnosis of and therapy for hepatocellular carcinoma].

Authors:  T F Greten; N P Malek; S Schmidt; J Arends; P Bartenstein; W Bechstein; T Bernatik; M Bitzer; A Chavan; M Dollinger; D Domagk; O Drognitz; M Düx; S Farkas; G Folprecht; P Galle; M Geißler; G Gerken; D Habermehl; T Helmberger; K Herfarth; R T Hoffmann; M Holtmann; P Huppert; T Jakobs; M Keller; J Klempnauer; F Kolligs; J Körber; H Lang; F Lehner; F Lordick; A Lubienski; M P Manns; A Mahnken; M Möhler; C Mönch; P Neuhaus; C Niederau; M Ocker; G Otto; P Pereira; G Pott; J Riemer; K Ringe; U Ritterbusch; E Rummeny; P Schirmacher; H J Schlitt; K Schlottmann; V Schmitz; A Schuler; H Schulze-Bergkamen; D von Schweinitz; D Seehofer; H Sitter; C P Straßburg; C Stroszczynski; D Strobel; A Tannapfel; J Trojan; I van Thiel; A Vogel; F Wacker; H Wedemeyer; H Wege; A Weinmann; C Wittekind; B Wörmann; C J Zech
Journal:  Z Gastroenterol       Date:  2013-11-15       Impact factor: 2.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.